Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice - Wikidata - awgldk - TriplyDB

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

http://www.wikidata.org/entity/Q33987268

about

Targeting Syk in Autoimmune Rheumatic Diseases Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus Functional roles of Syk in macrophage-mediated inflammatory responses Small molecules in the treatment of systemic lupus erythematosus Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis Fostamatinib Disodium.Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Getting Syk: spleen tyrosine kinase as a therapeutic target.T cells as therapeutic targets in SLE.Back to the future: oral targeted therapy for RA and other autoimmune diseases.Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV.Murine models of systemic lupus erythematosus The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.Current and novel therapeutics in the treatment of systemic lupus erythematosus Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.The role of Syk kinase in ultraviolet-mediated skin damage Abnormalities of T cell signaling in systemic lupus erythematosus.Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.T cells as a therapeutic target in SLE.Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.c-Jun and Ets2 proteins regulate expression of spleen tyrosine kinase in T cells.Novel treatments for systemic lupus erythematosus.Metabolic regulation of organelle homeostasis in lupus T cells B-cell selection and the development of autoantibodies.Taming lupus-a new understanding of pathogenesis is leading to clinical advances.Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1.Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.P-Selectin preserves immune tolerance in mice and is reduced in human cutaneous lupus.Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.Tyrosine kinases in rheumatoid arthritis.CREMα suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion.New and emerging therapies for acute and chronic graft versus host disease.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy

P2860

Q26751042-0471A5B5-C009-4D2D-B347-6E516889C910 Q26773124-D8300E31-9DC8-4816-ACF2-825BED646250 Q26851134-02E399CB-F8EF-4BDE-AE09-A32CA85E5392 Q27010090-FE0E84B4-1C66-4BF0-9653-82C1CAE283C0 Q28674280-983D2E18-2222-48E0-ADAD-A8C5CB29C66F Q33405080-C6D5274D-35D9-46A1-A2C4-732703D4D6D8 Q33620537-64A32FEE-C4FF-46AA-9719-47CC8D9FCD01 Q33993750-FD000DFF-2E69-418B-AAA6-C18A284410D2 Q34075552-F3407BB4-1A92-4AA2-9100-9F6C8822B39B Q34213332-01F4AB85-04A0-4FE0-94E4-C985A97362D4 Q34260045-6E2E3717-C73E-4D12-9471-EF9C491EF434 Q34538178-2FE55B97-9E86-4CAD-B046-ADEAF5136EC3 Q34591019-4C3F31DB-7DB1-4785-AF8B-EFD4EC871CAD Q34597949-7A3B7A41-22A7-4A98-9C2B-6D103AE0762F Q34648851-A915934E-5B37-4E1E-B3B4-502DEB623271 Q34980925-AA44C9EF-1111-4FC8-B876-C7A93F5AB75D Q35074699-F4EA4B97-2103-4996-A5D6-E50D1BAC758D Q35092855-B91AF955-F59E-4D14-A170-FB80AE19CDBA Q35172134-248F9911-8E86-4316-8AB3-5FA39A715757 Q35214963-82EFF870-9173-485D-8522-752BF2F0EA2F Q35809151-BA449E21-4CF7-4720-9D5C-E287996549A9 Q35836112-56B5BB1B-5FB3-401B-9BF5-FA5D8FB4F41E Q35874380-7A071E9D-1677-4F39-A147-42873DAFC298 Q36059553-BD959BA2-C22C-422B-A495-F39C5715A532 Q36177195-92632D69-BA40-4D7D-8922-74C4A04DD638 Q36504635-3E0A0949-48FC-4CE6-AB2C-C8A915AE2D3B Q36712941-9C8A16B1-5338-454F-8C2B-AA1137E27BC6 Q36844749-C3960834-A758-486C-80E7-92DE8AC8A7AC Q36907698-552875A7-153D-45DE-B494-7EB68555C262 Q37620637-4940EA72-AFF8-4232-9DA2-A2E46C14D293 Q37700471-30EC5C63-5A9B-4307-A346-CBC60BB5881D Q37826463-B0894081-8C63-4E21-A191-36AD475809B3 Q38366902-9DEAB5B5-285D-4458-8159-586010B662AF Q40134093-5DE1D0FF-4B11-4874-A81B-18BC343F686E Q41670053-E3F16E0D-9692-4A0C-9845-532F70337385 Q42623005-F94F05AA-2B0C-4D5E-A1D8-4CD80A4F8D66 Q49238507-77D519AB-2C65-4BDB-AEA7-D3B16232B853 Q55163735-F35881EB-380E-4786-9D10-8F4529FF5BDB Q55442953-B4C94B10-D5B2-4BEB-8DEF-E6EDDB40AB3B Q58775138-9AD73038-ACAB-4F3C-AC4A-6729B667FDAC

P2860

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

http://www.wikidata.org/entity/Q33987268

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@ast

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@en

type

label

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@ast

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@en

prefLabel

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@ast

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@en

P1433

Q33987268-76592C75-0611-4C19-84EC-F01A51CB2511

P1476

Q33987268-019196DF-6899-4CED-BA5E-498D627EBB88

P2093

Q33987268-0146F9B7-2B45-4948-95C8-239FBAE5E149

Q33987268-59BC64D6-47C3-4530-A837-AE3ABF5ED515

Q33987268-64932453-B079-4BFC-A45C-0F38FA774E4F

Q33987268-7D127768-7C30-4EDA-A5CB-4CA83E77A2B7

Q33987268-BA6416F8-A675-4716-B872-AB69C2759DAE

P2860

Q33987268-0DD06E61-F730-41D5-B996-B5119E6BAAEA

Q33987268-0EFAE1FF-8D30-4D95-96A4-5A7F5A4EC690

Q33987268-3C99E03A-0939-4A8D-9C58-B29E6F289249

Q33987268-3E623F34-E7DC-4A86-A11D-8625B047F417

Q33987268-52E60B22-936A-4B97-9723-11DEB44837D9

Q33987268-53CB06D6-317D-45C8-B7C6-86F0B61360CB

Q33987268-64F05876-DBAE-4699-BBBE-8903204B151E

Q33987268-6E2E75B7-55F7-4F09-A79D-0C9A16B570F1

Q33987268-813843FC-ACB0-45DA-975D-C5AE4C853934

Q33987268-829EC6B4-FC7D-422D-B466-E5256F503683

P304

Q33987268-B206333B-C1EF-4338-92CD-EF09D4632934

P31

Q33987268-B80B0E1A-96D9-4C9B-BE3B-E8A6E50C0923

P356

Q33987268-1847401D-35E9-47C4-8781-ABFD7988D1B8

P433

Q33987268-01D67339-CC90-43B1-9E02-441BA64E264B

P478

Q33987268-EC9A3EAB-F04E-45A9-B7AA-6F6291B92DC7

P577

Q33987268-9955865C-DC33-447C-BD00-8C12B7EFA337

P5875

Q33987268-32A818A0-97F8-4F50-B7CD-1D48181FB71F

P698

Q33987268-8323925A-978A-4D5E-A9BE-D3DC833E328B

P932

Q33987268-68DFF192-A9A4-4997-87D3-308EC2ACCF30

P356

P1433

Arthritis & Rheumatology

P1476

Suppression of skin and kidney ...... ine kinase in lupus-prone mice

@en

P2093

Frances Rena Bahjat

http://www.w3.org/2001/XMLSchema#string

George C Tsokos

http://www.w3.org/2001/XMLSchema#string

Guo-Min Deng

http://www.w3.org/2001/XMLSchema#string

Lena Liu

http://www.w3.org/2001/XMLSchema#string

Polly R Pine

http://www.w3.org/2001/XMLSchema#string

P2860

T cell activation

Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease

Syk tyrosine kinase required for mouse viability and B-cell development

Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling

Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Tyrosine kinases and their substrates in B lymphocytes.

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

SLP-76 couples Syk to the osteoclast cytoskeleton

P304

2086-2092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.27452

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41896792

http://www.w3.org/2001/XMLSchema#string

P698

20222110

http://www.w3.org/2001/XMLSchema#string

P932

2902591

http://www.w3.org/2001/XMLSchema#string